Sirolimus in solid organ transplantation: Current therapies and new frontiers

Massimiliano Veroux, Tiziano Tallarita, Daniela Corona, Antonio D'Assoro, Carmelina Gurrieri, Pierfrancesco Veroux

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Sirolimus (SRL) is a mammalian target of rapamycin inhibitor, which provides an immunosuppressive effect by inhibiting cell cycle progression. The encouraging results of combined SRL-cyclosporine therapy paved the way to further immunosuppressant combinations. Although SRL is relatively non-nephrotoxic when administered as monotherapy, it pharmacodynamically enhances the toxicity of calcineurin inhibitors. Other side effects may include hyperlipidemia and myelosuppression and less commonly wound healing impairment, proteinuria, edema and pneumonitis. Surprisingly, SRL also showed encouraging properties as an antiatherogenic and antineoplastic, opening a large spectrum of new potential applications. Whether SRL can be used safely over the long term with low doses of calcineurin inhibitors requires further study. The use of SRL as a corticosteroid-sparing agent also remains to be proven in controlled trials.

Original languageEnglish (US)
Pages (from-to)1487-1497
Number of pages11
JournalImmunotherapy
Volume3
Issue number12
DOIs
StatePublished - Dec 1 2011

Fingerprint

Organ Transplantation
Sirolimus
Immunosuppressive Agents
Therapeutics
Hyperlipidemias
Proteinuria
Antineoplastic Agents
Wound Healing
Cyclosporine
Edema
Pneumonia
Cell Cycle
Adrenal Cortex Hormones

Keywords

  • cancer
  • heart transplantation
  • kidney transplantation
  • lung transplantation
  • lymphocele
  • pediatric transplantation
  • pneumonitis
  • proteinuria
  • sirolimus
  • transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Veroux, M., Tallarita, T., Corona, D., D'Assoro, A., Gurrieri, C., & Veroux, P. (2011). Sirolimus in solid organ transplantation: Current therapies and new frontiers. Immunotherapy, 3(12), 1487-1497. https://doi.org/10.2217/imt.11.143

Sirolimus in solid organ transplantation : Current therapies and new frontiers. / Veroux, Massimiliano; Tallarita, Tiziano; Corona, Daniela; D'Assoro, Antonio; Gurrieri, Carmelina; Veroux, Pierfrancesco.

In: Immunotherapy, Vol. 3, No. 12, 01.12.2011, p. 1487-1497.

Research output: Contribution to journalReview article

Veroux, M, Tallarita, T, Corona, D, D'Assoro, A, Gurrieri, C & Veroux, P 2011, 'Sirolimus in solid organ transplantation: Current therapies and new frontiers', Immunotherapy, vol. 3, no. 12, pp. 1487-1497. https://doi.org/10.2217/imt.11.143
Veroux, Massimiliano ; Tallarita, Tiziano ; Corona, Daniela ; D'Assoro, Antonio ; Gurrieri, Carmelina ; Veroux, Pierfrancesco. / Sirolimus in solid organ transplantation : Current therapies and new frontiers. In: Immunotherapy. 2011 ; Vol. 3, No. 12. pp. 1487-1497.
@article{8f539ddcd1304b4a997e59d3ca7f21ed,
title = "Sirolimus in solid organ transplantation: Current therapies and new frontiers",
abstract = "Sirolimus (SRL) is a mammalian target of rapamycin inhibitor, which provides an immunosuppressive effect by inhibiting cell cycle progression. The encouraging results of combined SRL-cyclosporine therapy paved the way to further immunosuppressant combinations. Although SRL is relatively non-nephrotoxic when administered as monotherapy, it pharmacodynamically enhances the toxicity of calcineurin inhibitors. Other side effects may include hyperlipidemia and myelosuppression and less commonly wound healing impairment, proteinuria, edema and pneumonitis. Surprisingly, SRL also showed encouraging properties as an antiatherogenic and antineoplastic, opening a large spectrum of new potential applications. Whether SRL can be used safely over the long term with low doses of calcineurin inhibitors requires further study. The use of SRL as a corticosteroid-sparing agent also remains to be proven in controlled trials.",
keywords = "cancer, heart transplantation, kidney transplantation, lung transplantation, lymphocele, pediatric transplantation, pneumonitis, proteinuria, sirolimus, transplantation",
author = "Massimiliano Veroux and Tiziano Tallarita and Daniela Corona and Antonio D'Assoro and Carmelina Gurrieri and Pierfrancesco Veroux",
year = "2011",
month = "12",
day = "1",
doi = "10.2217/imt.11.143",
language = "English (US)",
volume = "3",
pages = "1487--1497",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - Sirolimus in solid organ transplantation

T2 - Current therapies and new frontiers

AU - Veroux, Massimiliano

AU - Tallarita, Tiziano

AU - Corona, Daniela

AU - D'Assoro, Antonio

AU - Gurrieri, Carmelina

AU - Veroux, Pierfrancesco

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Sirolimus (SRL) is a mammalian target of rapamycin inhibitor, which provides an immunosuppressive effect by inhibiting cell cycle progression. The encouraging results of combined SRL-cyclosporine therapy paved the way to further immunosuppressant combinations. Although SRL is relatively non-nephrotoxic when administered as monotherapy, it pharmacodynamically enhances the toxicity of calcineurin inhibitors. Other side effects may include hyperlipidemia and myelosuppression and less commonly wound healing impairment, proteinuria, edema and pneumonitis. Surprisingly, SRL also showed encouraging properties as an antiatherogenic and antineoplastic, opening a large spectrum of new potential applications. Whether SRL can be used safely over the long term with low doses of calcineurin inhibitors requires further study. The use of SRL as a corticosteroid-sparing agent also remains to be proven in controlled trials.

AB - Sirolimus (SRL) is a mammalian target of rapamycin inhibitor, which provides an immunosuppressive effect by inhibiting cell cycle progression. The encouraging results of combined SRL-cyclosporine therapy paved the way to further immunosuppressant combinations. Although SRL is relatively non-nephrotoxic when administered as monotherapy, it pharmacodynamically enhances the toxicity of calcineurin inhibitors. Other side effects may include hyperlipidemia and myelosuppression and less commonly wound healing impairment, proteinuria, edema and pneumonitis. Surprisingly, SRL also showed encouraging properties as an antiatherogenic and antineoplastic, opening a large spectrum of new potential applications. Whether SRL can be used safely over the long term with low doses of calcineurin inhibitors requires further study. The use of SRL as a corticosteroid-sparing agent also remains to be proven in controlled trials.

KW - cancer

KW - heart transplantation

KW - kidney transplantation

KW - lung transplantation

KW - lymphocele

KW - pediatric transplantation

KW - pneumonitis

KW - proteinuria

KW - sirolimus

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=81855173480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855173480&partnerID=8YFLogxK

U2 - 10.2217/imt.11.143

DO - 10.2217/imt.11.143

M3 - Review article

C2 - 22091684

AN - SCOPUS:81855173480

VL - 3

SP - 1487

EP - 1497

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 12

ER -